Overview

Gender

male

Head of the Institute of Emerging Diseases and Innovative Therapies of CEA and INSERM; Professor of Medicine, University of Paris; and Visiting Professor, Harvard
Philippe Leboulch is a scientific founder of bluebird bio. He serves as the co-chairman of its Scientific Advisory Board and leader of the LentiGlobin® project. He is a professor of medicine and cell biology at the University of Paris and visiting professor at Harvard Medical School. Philippe is also the director of the Institute of Emerging Diseases and Innovative Therapies of the CEA near Paris and director of an INSERM research unit. He maintains a research laboratory in the genetics division of the Brigham & Women's Hospital at Harvard Medical School, where he previously served as a full-time faculty member for 15 years after a postdoctoral fellowship at MIT. Philippe is an expert in vectorology and hematopoietic gene therapy, with special emphasis on the beta-hemoglobinopathies. He has been published extensively in high-impact journals and is a regularly invited speaker at major international conferences. Philippe was a member of the Editorial Board of Blood, the Journal of the American Society of Hematology. He has served on major committees of the National Institutes of Health and the American Society of Gene Therapy. Philippe has received numerous NIH grant awards and prizes that include the Grand Prize Etancelin of the French National Academy of Sciences.